Evidence map›Paper›PMID 40141052›Full record

ArticleInternational journal of molecular sciences2025

Novel Phenotypical and Biochemical Findings in Mucolipidosis Type II.

Eines Monteagudo-Vilavedra, Daniel Rodrigues, Giorgia Vella, Susana B Bravo, Carmen Pena, Laura Lopez-Valverde, Cristobal Colon, Paula Sanchez-Pintos, Francisco J Otero Espinar, Maria L Couce and 1 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Eines Monteagudo-VilavedraMetabolopathies Platform, IDIS-Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain.ORCID 0000-0001-5148-0276
Daniel RodriguesMetabolopathies Platform, IDIS-Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain.ORCID 0000-0002-2934-1699
Giorgia VellaMetabolopathies Platform, IDIS-Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain.
Susana B BravoDepartment of Forensic Sciences, Pathology, Gynecology and Obstetrics, Pediatrics, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain.ORCID 0000-0001-7615-3079
Carmen PenaProteomic Platform, IDIS-Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain.
Laura Lopez-ValverdeMetabolopathies Platform, IDIS-Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain.
Cristobal ColonMetabolopathies Platform, IDIS-Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain.ORCID 0000-0002-9711-2812
Paula Sanchez-PintosMetabolopathies Platform, IDIS-Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain.ORCID 0000-0003-4992-1305
Francisco J Otero EspinarParaquasil Platform, IDIS-Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain.ORCID 0000-0001-9030-2253
Maria L CouceMetabolopathies Platform, IDIS-Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain.ORCID 0000-0003-4861-9905
J Victor AlvarezMetabolopathies Platform, IDIS-Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain.ORCID 0000-0003-3735-1341

Funding

Instituto de Salud Carlos III CD22/00160Kaertor foundation No numberMPS Lisosomales no number
6 · The paper itself

Abstract

Mucolipidosis type II is a very rare lysosomal disease affecting the UDP-GlcNAc N-acetylglucosamine-1-phosphotransferase enzyme, which catalyzes the synthesis of the targeting signal mannose 6-phosphate in lysosomal acid hydrolases. Its deficiency hinders the arrival of lysosomal enzymes to the lysosome, diminishing the multiple degradations of components that cells need to perform. Due to the low prevalence of this condition, available information is scarce. This article aims to deepen the understanding of the disease; clinical, biochemical, and proteomic data are analyzed. Three patients have been identified presenting

Indexed as

MucolipidosesTransferases (Other Substituted Phosphate Groups)Dried Blood Spot TestingExome SequencingFemaleGlycosaminoglycansHumansMalePhenotypeProteomicsGlycosaminoglycansGNPTAB protein, humanTransferases (Other Substituted Phosphate Groups)biochemistrybiomarkersearly findingslysosomal diseasesmucolipidosis II-IIIproteomic studies

Identifiers

PMID40141052
PMCPMC11941985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.